Seroprevalencia de virus varicela-zoster en niños con cáncer
en seis hospitales de Santiago, Chile
Author
dc.contributor.author
Izquierdo Copiz, Giannina
Author
dc.contributor.author
Zubieta, Marcela
Author
dc.contributor.author
Martínez G., María J.
Author
dc.contributor.author
Álvarez, Ana M.
Author
dc.contributor.author
Avilés, Carmen L.
Author
dc.contributor.author
Becker, Ana
Author
dc.contributor.author
Peña, Mónica
Author
dc.contributor.author
Salgado Muñoz, Carmen
Author
dc.contributor.author
Silva, Pamela
Author
dc.contributor.author
Topelberg, Santiago
Author
dc.contributor.author
Tordecilla Cadiu, Juan
Author
dc.contributor.author
Varas Palma, Mónica
Author
dc.contributor.author
Villarroel, Milena
Author
dc.contributor.author
Viviani, Tamara
Author
dc.contributor.author
Santolaya de Pablo, María Elena
Admission date
dc.date.accessioned
2018-12-20T14:53:17Z
Available date
dc.date.available
2018-12-20T14:53:17Z
Publication date
dc.date.issued
2012
Cita de ítem
dc.identifier.citation
Revista Chilena de Infectología, 2012; 29 (6): 595-599
Identifier
dc.identifier.issn
07161018
Identifier
dc.identifier.other
10.4067/S0716-10182012000700002
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/157316
Abstract
dc.description.abstract
Infections with varicella-zoster virus (VVZ) in immunocompromised children imply a high mortality. There
is no data about VVZ seroprevalence in children with cancer in our country. Aim: To determine the prevalence of
VVZ antibodies in children with cancer who have undergone chemotherapy or have undergone a hematopoietic
stem cell transplant. Methodology: collaborative, multicenter study. Serum samples were collected from 281
children with cancer and episodes of febrile neutropenia from 6 hospitals belonging to the public health network
in the Metropolitan Region between June 2004 and August 2006. These samples were stored at -70 º C, and 200
of them were randomly chosen and analyzed to determine VVZ IgG (ELISA). Results: 179 samples from 179
children, 65% male. Ninety eigth/179 (55%) were positive, 72/179 (40%) negative and 9/179 (5%) indeterminate.
Stratified by age, seropositive percentage was: 1 to 4 years 32%, 5-9 years 42%, 10-14 years 78%, over 15 years
88%. Conclusion: Forty percent of children treated for cancer are seronegative to VVZ infection, a frequency that
decreases with age. These results support the adoption of preventive measures to avoid infection in this population
of children at risk of developing a serious and possibly fatal illness.